As Biotechnology businesses, Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Amarin Corporation plc (NASDAQ:AMRN), are affected by contrast. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paratek Pharmaceuticals Inc.	17.12M	11.78	112.36M	-3.64	0.00
Amarin Corporation plc	229.21M	26.98	116.44M	-0.34	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Paratek Pharmaceuticals Inc. and Amarin Corporation plc.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%
Amarin Corporation plc	-50.80%	827.8%	-45.9%

Risk and Volatility

Paratek Pharmaceuticals Inc. is 71.00% more volatile than Standard & Poor’s 500 due to its 1.71 beta. In other hand, Amarin Corporation plc has beta of 1.31 which is 31.00% more volatile than Standard & Poor’s 500.

Liquidity

Paratek Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 11.4 and 11.4 respectively. The Current Ratio and Quick Ratio of its competitor Amarin Corporation plc are 2.4 and 2 respectively. Paratek Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Amarin Corporation plc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Paratek Pharmaceuticals Inc. and Amarin Corporation plc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Paratek Pharmaceuticals Inc.	0	0	4	3.00
Amarin Corporation plc	0	0	4	3.00

The upside potential is 241.64% for Paratek Pharmaceuticals Inc. with average price target of $21.25. Competitively the average price target of Amarin Corporation plc is $34.2, which is potential 82.11% upside. Based on the data delivered earlier, Paratek Pharmaceuticals Inc. is looking more favorable than Amarin Corporation plc, analysts view.

Insider and Institutional Ownership

The shares of both Paratek Pharmaceuticals Inc. and Amarin Corporation plc are owned by institutional investors at 77.7% and 49.1% respectively. Paratek Pharmaceuticals Inc.’s share owned by insiders are 3.1%. Insiders Competitively, owned 0.9% of Amarin Corporation plc shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%
Amarin Corporation plc	9.7%	22.8%	24.22%	567.39%	537.69%	57.9%

For the past year Paratek Pharmaceuticals Inc. was less bullish than Amarin Corporation plc.

Summary

On 7 of the 11 factors Amarin Corporation plc beats Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.